Details for 2017194307

Up to date per 05.04.2026

Actions

Title / Product Name

2-(2,4,5-SUBSTITUIERTES-ANILIN)PYRIMIDIN-DERIVATE ALS EGFR-MODULATOREN ZUR BEHANDLUNG VON KREBS

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2017194307

EP Publication Number

3333161

E-Number

1234836

Language

PCT Number

Publication Date

13.06.2018 A

19.02.2020 B1

Registration Date

19.02.2020

AT Publication Date

15.03.2020

Application Date

25.07.2012

Registration Number

Priorities

27.07.2011

201161512061 P

27.01.2012

201261591363 P

IPC

C07D 401/02 20060101AFI20180303BHEP

Maximum Duration of Protection

25.07.2032

Owner

Astrazeneca AB 151 85 SödertäljeSE

Representative

Häupl & Ellmeyer KG, PatentanwaltskanzleiMariahilfer Straße 50 (Eingang Kirchengasse 1)1070 WienAT

Inventor

BUTTERWORTH, Samc/o AstraZeneca Intellectual Property, AstraZeneca Alderley Park Macclesfield, Cheshire SK10 4TGGB

WARD, Richard, AndrewAstraZeneca Darwin Building Cambridge Science Park, Milton Road Cambridge, Cambridgeshire CB4 0WGGB

FINLAY, Maurice, Raymond, VerschoyleAstraZeneca, Darwin Building Cambridge Science Park, Milton Road Cambridge, Cambridgeshire CB4 0WGGB

KADAMBAR, Vasantha, KrishnaAstraZeneca Alderley Park Macclesfield, Cheshire SK10 4TGGB

CHINTAKUNTLA, Chandrasekhara, ReddyAstraZeneca Alderley Park Macclesfield, Cheshire SK10 4TGGB

MURUGAN, AndiappanAstraZeneca Alderley Park Macclesfield, Cheshire SK10 4TGGB

CHUAQUI, Claudio, EdmundoAstraZeneca 35 Gatehouse Drive Waltham, MA 02451US

REDFEARN, Heather, MarieAstraZeneca Charter Way Macclesfield, Cheshire SK10 2NAGB

Information about Fees